Kestra Medical Technologies, Ltd.: stock overview

KMTSNASDAQHealthcare · Surgical & Medical Instruments & Apparatus

Price

$28.64

November 13, 2026Market cap $1.7B

DCF calculator

What Ploutos Investor adds for Kestra Medical Technologies

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 3 fiscal years, from FY2024
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.

In short

Kestra Medical Technologies had revenue of $107M over the last 12 months and a net loss of $150M. Revenue grew by 84.9% a year on average over the last 2 years. It pays no dividend.

From its SEC filings (latest fiscal year to April 30, 2026) and the price of November 13, 2026.

Its SEC filings
Market cap
$1.7B
58.60M shares
P/E
–
Revenue, 12 months
$107M
+84.9% a year over 2 years
Net margin
-140.4%
FY2025: -138.4%, above 2% of its industry

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

FY2024–FY2026 fiscal years

+84.9% a year over 2 years

  • FY2026Apr 30, 202610-K
    Revenue$95M
  • FY2025Apr 30, 202510-K
    Revenue$60M
  • FY2024Apr 30, 2024
    Revenue$28M

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 
$1.7B
Enterprise value 
–
P/E 
–
EV / EBIT 
–
EV / Revenue 
–
P/B 
7.6
FCF yield 
–
Earnings yield 
–

Profitability

Gross margin 
53.9%
Operating margin 
-134.5%
Net margin 3-year median: -190.3%
-140.4%
ROIC 
-41.7%
ROIC, 5-year average 
-34.7%
ROE 
-67.0%

Growth

Revenue, yearly change 
+59.0%
EPS, yearly change 
–
FCF, yearly change 
–
Revenue, average a year 
+84.9%

The yearly change compares FY2026 with FY2025.

Balance sheet

Cash 
$245M
Total debt 
–
Net cash 
–
Net debt / EBITDA 
–
Interest cover 
-19.0x
Current ratio 
4.69

Balance sheet of July 31, 2026.

Returns to shareholders

Dividend yield 
0.00%
Buybacks 
–
Total returned 
0.00%
Shares, yearly change 
+14.1%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

Against its industry

Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 38).

Gross margin

51.4%

Above 38% of the 161 companies in its industry, and 70% of all.

Operating margin

-141.6%

Above 2% of the 186 companies in its industry, and 2% of all.

Net margin

-138.4%

Above 2% of the 189 companies in its industry, and 2% of all.

ROE

-45.7%

Above 16% of the 174 companies in its industry, and 8% of all.

ROA

-34.7%

Above 10% of the 190 companies in its industry, and 5% of all.

Revenue growth

59.0%

Above 98% of the 186 companies in its industry, and 96% of all.

From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
KESTRA MEDICAL TECHNOLOGIES, LTD.
CIK
1877184
Exchange
NASDAQ
Industry (SIC)
3841 · Surgical & Medical Instruments & Apparatus
Fiscal year ends
April 30
Latest annual report
April 30, 2026
Reporting currency
USD
Shares
58.60M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do Kestra Medical Technologies's filings show?

These are Kestra Medical Technologies's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about KMTS

Didn't find what you were looking for?

Ask us
What is KMTS's market cap?

Kestra Medical Technologies, Ltd.'s market cap is $1.7B, at a price of $28.64 on November 13, 2026 and 58.60M shares.

How much revenue does KMTS have?

Kestra Medical Technologies had revenue of $107M over the last 12 months. Over the last 2 years it changed by +84.9% a year on average.

Does KMTS pay a dividend?

No. Kestra Medical Technologies paid no regular dividend over the last 12 months.

Where do the figures come from?

From Kestra Medical Technologies, Ltd.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.